%0 Journal Article
%T Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
%A Kenneth LaPensee
%A Rohit Mistry
%A Thomas Lodise
%J Archive of "American Health & Drug Benefits".
%D 2019
%X Omadacycline is an oral and intravenous (IV) once-daily aminomethylcycline antibiotic that is approved in the United States for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). It has broad-spectrum activity against common causative pathogens of ABSSSI, including methicillin-resistant Staphylococcus aureus. Omadacycline has been shown to be noninferior to linezolid for the treatment of adults with ABSSSI across 2 phase 3 clinical trials. To date, no studies have assessed the budget impact for omadacycline in the treatment of ABSSSI
%K acute bacterial skin and skin structure infections (ABSSSI)
%K antibacterial agents
%K budget impact model
%K cost analysis
%K omadacycline
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442091/